PEP-Therapy
Innovative peptides
as targeted therapies for oncology
LATEST NEWS
September 3rd, 2024
We are thrilled to announce the publication of our work in Frontiers in Pharmacology, showing that our lead product, PEP-010, is effective in monotherapy and in combination with paclitaxel in resistant ovarian adenocarcinoma.
+ READ MORE
June 4th, 2024
We are happy to share updates on our PEP-010 program at the EACR Annual Meeting which will be held June 10-13 in Rotterdam, Netherlands.
Come and visit our posters!
May 30th, 2024
PEP-Therapy appoints Hatem Azim, MD, PhD, as Chief Medical Officer.
+ READ MORE
